More Videos
SPECIAL REPORT
MOST SHARED
- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- Today's Market Action
- Has Twitter's Finest Hours (Seconds) Come and Gone?
- CNBC TRANSCRIPT: Warren Buffett & Bill Gates - Keeping America Great
- Microsoft's Bill Gates Praises Apple's Steve Jobs For 'Saving the Company'
- Israel Going Green
- Inside Wal-Mart's Acai Berry Juice Maker
- Low Interest Rate Investing
- China's Role as Lender Alters Dynamics for United States
- U.S. Stocks Rally for the Second Straight Week
- Dollar is Not Plunging—So 'Calm Down': Market Strategist
- Strategists Say Markets Have More Upside — But How Much?
- Hirschhorn: Risk-Averse Traders
- Roginsky: A Funny Thing Happened on the Way to Financial Reform
- This Year's Biggest Thanksgiving Leftover: Cash
- TV Series Inks Unique Deal For Fight
- First Time Buyers Rescue Housing: Realtors
- Dollar General Trades Higher After Its IPO
- White House Plans to Freeze Spending to Cut Deficit
- Week Ahead: Investors Go for Quality, Assess Recovery
- Hedge Fund Billionaire Paulson Reports New Citi Stake
- Cramer: 5 Earnings Reports to Watch Next Week
- Court Rejects 'Clawbacks' for Alleged Stanford Victims
- Cities With the Most Home Price Reductions
- Tax Credit Sparking First-Time Home Sales: Realtors
- Investors Cut Back US Stocks for Bigger Growth Abroad
- This Year's Biggest Thanksgiving Leftover: Cash
RSS FEED
Pharma's Market
Text Size 
 |
Yoda |
At the end of his speech in the opening session, the outgoing president of the organization played a "Star Wars" clip with the sage saying, "Try not. Do or do not. There is no try." He was trying to make a point about the ACC's role in forging healthcare reform.
But many--especially, I suspect, folks at Merck [MRK
Loading...
()
] and Schering-Plough-[SGP
Loading...
()
] --would argue the ACC tried, but did not do when it comes to the promised "reasoned" panel discussion of the controversial Vytorin/Zetia test results.
It was standing room only in the great hall for the "showcase session," although the fire marshal shooed away people who were standing four and five deep in the wide doorways. They came to hear the data presentation and then an airing-out of the results by an ACC handpicked panel of experts.
But the second part never happened. One of the experts, Dr. Harlan Krumholz, launched into prepared remarks during which he suggested that Zetia could be nothing more than an "expensive placebo." Those are his words. Another panel member put a brief button on Dr. Krumholz's speech and that was it. No discussion. No q and a. The room, packed with by my estimate about 6,000 people, emptied out in a hurry.
Damage was done.
Credit Suisse analyst Catherine Arnold writes in a research note to clients this morning, "...the expected 'panel discussion' had almost no 'discussion', rather it seemed like a (Zetia)-bashing session...." Because of that Arnold now believes a Vytorin/Zetia "recovery" will require patience and as a result she's taking a scalpel to her earnings estimates for both companies.
Credit Suisse has done and wants to do more investment banking for MRK and SGP. And Arnold or someone on her team lives with a Schering employee.
May the sales force be with Merck and Schering-Plough.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes